drugset / Trial / NCT05330065
A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion
NaSingle-groupOpen-labelTreatment
Summary
Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can cause significant symptoms and result in a marked decrease in quality of life and a poor prognosis. MPE is primarily considered as an immune and vascular manifestation of pleural metastases. The combined use of anti-angiogenic therapy and immunotherapy may be a promising strategy for MPE. This is a Phase Ib/II clinical trial to evaluate the safety and tolerability of administering bevacizumab and camrelizumab into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-08-31
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Other |
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Other |
| Subject | Camrelizumab | Monoclonal antibody | 100 mg | Other |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Other |